HLB bioStep KRX:278650KOSDAQ
HLB바이오스텝 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, HLB bioStep reported revenue of ₩16.0bn, down 10.2% year on year, and an operating loss of ₩1.9bn. HLB bioStep (HLB바이오스텝) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article.
HLB bioStep quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩16.0bn | -10.2% | −₩1.9bn | −₩3.5bn |
| Q1 2026 | ₩13.5bn | -0.7% | −₩2.6bn | −₩2.1bn |
| Q4 2025 derived | ₩18.7bn | +16.0% | −₩2.2bn | −₩14.5bn |
| Q3 2025 | ₩24.0bn | +29.3% | ₩455m | ₩770m |
| Q2 2025 | ₩17.8bn | +49.0% | −₩4.3bn | −₩4.6bn |
| Q1 2025 | ₩13.6bn | +17.4% | −₩2.5bn | −₩1.8bn |
| Q4 2024 derived | ₩16.1bn | +9.6% | −₩4.7bn | −₩3.4bn |
| Q3 2024 | ₩18.5bn | +69.3% | −₩2.7bn | −₩830m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
HLB bioStep top stories 2 weeks, by number of outlets
- 1
